AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04252053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Based Core Stabilization Training
Description: Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
Study NCT04252053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise
Description: Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
Study NCT03147781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True AT with magnetic pellets
Description: Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
Study NCT03147781 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AT with Medulla Junci
Description: Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
Study NCT00631020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBME
Description: 6 weeks of once a week one-on-one CBME
Study NCT00631020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional NRT
Description: NicoDerm CQ nicotine transdermal patch
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Saccharomyces boulardii
Study NCT03220542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: Broccoli sprouts extract
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin
Study NCT03220542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin
Study NCT03279614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
Study NCT00507390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Description: 2g n-3 PUFAs once daily for 8 weeks
Study NCT00507390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: 1 capsule day
Study NCT03221751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prazosin hydrochloride
Description: Prazosin is an oral capsule. It is an alpha-1 antagonists.
Study NCT03221751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is an inert oral capsule identical in appearance to prazosin capsules.
Study NCT03986385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Capecitabine Oxaliplatin
Description: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
Study NCT03986385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Oxaliplatin
Description: Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
Study NCT00131469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide (FORTEO)
Description: Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
Study NCT00131469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT01063075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously
Study NCT01063075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered Intravenously
Study NCT01063075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - FU
Description: Administered Intravenously
Study NCT04868721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations
Description: three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
Study NCT02769663 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires and neuropsychological assessments
Study NCT04206605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching lanadelumab SC injection.
Study NCT04206605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab solution in a PFS for injection.
Study NCT05111665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Study NCT05111665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Group Therapy (RGT)
Study NCT05111665 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 45 mg/m^2
Description: Paclitaxel 45 mg/m\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC6
Description: Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: Cisplatin 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: Pemetrexed 500 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
Study NCT03631784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy (TRT)
Description: The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m^2
Description: Paclitaxel 200 mg/m\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
Study NCT03631784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC2
Description: Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
Study NCT01730508 — intervention group
Intervention type: DRUG
Intervention: Pegylated Interferon Alfa (Peginterferon Alfa)
Description: Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
Study NCT00618410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide, USP
Description: Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
Study NCT00618410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal placebo
Study NCT00585611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin - 40 mg orally daily for 6 months
Study NCT00585611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin - 40 mg orally daily for 6 months
Study NCT00585611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04196075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata
Description: AP as palliative treatment
Study NCT01610895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions
Description: Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed.
Study NCT01610895 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions
Description: Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed.
Study NCT03199040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -Human monoclonal antibody
Study NCT03199040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Description: -The vaccine will be given by the TDS-IM system
Study NCT03199040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM system (Inchor Medical Systems)
Description: -At each vaccination time point, patients will receive two injections at separate sites.
Study NCT03199040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
Study NCT04265716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical L. reeuteri
Description: Tubes with ointment containing L. reuteri DSM17938
Study NCT04265716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical L. reeuteri
Description: Tubes with ointment containing L. reuteri DSM17938
Study NCT01252212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS medication adherence
Description: SMS messages to cell phones.
Study NCT01252212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No SMS adherence reminder
Description: In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
Study NCT03700320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) Migraine Preventive Medication
Description: Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
Study NCT03700320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant tablets taken orally, once daily for 52 weeks.
Study NCT04251910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual film containing Dexmedetomidine
Description: Sublingual film containing Dexmedetomidine
Study NCT04251910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo Film
Description: Sublingual placebo film that matches BXCL501
Study NCT01709084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
Study NCT01935778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and capecitabine and oxaliplatin
Description: Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
Study NCT04303130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days).
Study NCT03880942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative story book
Description: Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
Study NCT03880942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Informative Story Book
Description: Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
Study NCT02910947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided quadratus lumborum or Transversus Abdominis plane block
Description: The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
Study NCT03300895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
Study NCT03300895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Moderate-intensity continuous exercise
Description: 30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
Study NCT01664988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscular relaxation
Description: muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
Study NCT01664988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breath control
Description: breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
Study NCT01664988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control (routine care)
Description: received routine care of clinic or health center and use drugs if necessary
Study NCT04101279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical management of stress urinary incontinence with midurethral tension free tape.
Description: Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
Study NCT04101279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.
Description: Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
Study NCT00589420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00589420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT03375398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice
Description: Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water
Study NCT03375398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugardown™
Description: Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
Study NCT00243386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
Study NCT00243386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
Study NCT02707380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
Study NCT02707380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: 3 exercises that do not include these 7 muscle-strengthening exercises
Study NCT04276389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided paclitaxel drug-coated balloon angioplasty
Description: OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
Study NCT04276389 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angiography-guided paclitaxel drug-coated balloon angioplasty
Description: Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
Study NCT01637220 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood volume collected specifically for this study
Description: * case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~* Control patients: 20 ml following neuromuscular blocking drug injection
Study NCT03422432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
Study NCT03908320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual Cycle Timing
Description: Quit date is set to menstrual phase.
Study NCT03908320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menstrual Cycle Timing
Description: Menstrual cycle timing of quit date is monitored
Study NCT03908320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRT Patch
Description: NRT patch is provided
Study NCT03908320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT Patch
Description: NRT patch is provided
Study NCT03908320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation Counseling
Description: Cessation counseling is provided
Study NCT03908320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Cessation counseling is provided
Study NCT01450449 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 25 Gy in 5 daily fractions over 1 week
Study NCT01450449 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 40 Gy in 15 daily fractions over 3 weeks
Study NCT00966342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluviral 2009/10
Description: single dose given IM .05 mL
Study NCT04532476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators.